New award for levothyroxine NA tablets with xlcare pharmaceuticals, INC. Base year ordering period is JAN 27, 2025 through JAN 26, 2026 with four one-year options
Active Indefinite Delivery Contract Awarded Last action
- Contract number
- 36E79725D0004
- Awardee
-
Xlcare Pharmaceuticals Inc. UEI MEAUS5WHBJJ7
- Awarding agency
-
National Acquisition Center
Headquarters, Department of Veterans Affairs
- Task orders
- 0
Award facts
- Opportunity
-
- 6505--Levothyroxine Tablets (VA-24-00084562) Pre-Solicitation · 36E79724R0020 · Posted Aug 27, 2024
- Last date to order 90% complete
- IDV ceiling
- $40,144,392.00
- Award type
- Single award
- Contracting staff
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 3 offers Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
Award details come from SAM.gov/FPDS.
About this IDV
The Department of Veterans Affairs National Acquisition Center awarded a single-award indefinite-delivery contract to Xlcare Pharmaceuticals Inc. for levothyroxine sodium tablets on January 27, 2025, with a ceiling value of $40,144,392.
The contract carries no set-aside designation. Performance encompasses distribution through the VA's Pharmaceutical Prime Vendor Program to VA medical centers nationwide. The procurement originated from an unrestricted RFP solicitation for levothyroxine sodium tablets under NAICS code 325412, with estimated annual requirements ranging from 3,648 to 282,262 bottles or blister packs across 12 line items. The VA sought a single responsible offeror capable of providing an uninterrupted source of supply.
The period of performance runs from January 27, 2025 through January 26, 2026 as the base year, with four one-year option periods. The contract is scheduled for ultimate completion on January 16, 2027. The award incorporated Section 5 of Executive Order 14398 and FAR clause 52.222-90, addressing discrimination and diversity and equity initiatives. Xlcare Pharmaceuticals Inc. is certified as an economically disadvantaged woman-owned small business and registered as a minority-owned, small disadvantaged business.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | $0 | |
| Exercise an Option | $0 | |
| Original award | $0 |
Quick answers
Who was awarded contract 36E79725D0004?
36E79725D0004 was awarded to Xlcare Pharmaceuticals Inc. by National Acquisition Center (Headquarters) on January 27, 2025.
How much is contract 36E79725D0004 worth?
36E79725D0004's own ceiling is $40,144,392.
Who can order from contract 36E79725D0004?
36E79725D0004 is a single award indefinite delivery contract.
Was contract 36E79725D0004 competed?
The extent of competition for 36E79725D0004 was full and open competition. The government received 3 offers.
On GovTribe
See this IDV's full record
- Every order and transaction
- The awardee's other awards and teaming partners
- Similar IDVs and recompete opportunities
- Ask GovTribe AI about this IDV